Skip to main content

Table 1 Clinical correlation of miR-410-3p expression in cancer patients

From: miR-410-3P inhibits adipocyte differentiation by targeting IRS-1 in cancer-associated cachexia patients

  miR-410-3p   
Features Low (n = 30) Higha (n = 30) t/χ2 P
Gender    4.8 0.028
Male 16 24   
Female 14 6   
Age (years)    0.606 0.436
> 65 12 15   
≤ 65 18 15   
Tumor stage    8.531 0.003
I + II 17 6   
III + IV 13 24   
Weight (kg) 62.3 ± 8.06 59.73 ± 11.6 0.834 0.410
BMI (kg/m2) 22.6 ± 2.55 21.71 ± 2.2 1.144 0.260
Body weight loss (%) 0.23 ± 0.09 9.76 ± 4.12 11.862 < 0.001
IL-6 (pg/mL) 3.81 ± 1.78 6.96 ± 2.74 2.385 0.024
TNF-a (pg/mL) 9.57 ± 5.98 12.45 ± 7.83 1.164 0.253
TP (g/L) 65.21 ± 5.44 64.27 ± 4.77 0.57 0.574
ALB (g/L) 41.57 ± 4.41 39.1 ± 3.92 1.947 0.044
  1. aAccording to the median expression level of miR-410-3p in all patients, the expression with lower than 50th percentile was classified as low expression group; the patients with higher than 50th percentile was classified as high expression group